This 2018 open-label, phase 2, multicohort study evaluated the efficacy of bipolar androgen therapy (BAT) in 30 men with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after enzalutamide treatment. BAT involved intramuscular testosterone cypionate (400 mg every 28 days) combined with luteinizing hormone-releasing hormone agonist therapy. The primary endpoint,
